Patients aged 60 years or older who present with therapy-related acute myeloid leukaemia (tAML) or acute myeloid leukaemia with myelodysplasia-related changes (MRC-AML) represent a distinct, high-risk group for whom standard induction approaches do not apply. This first-line protocol addresses their specific management.
The patient is aged 60 years or older and carries a confirmed diagnosis of therapy-related AML or AML with myelodysplasia-related changes. This group — which includes those with certain molecular mutation profiles — is managed under dedicated first-line guidance distinct from de-novo AML protocols.
Induction uses a specific liposomal formulation recommended for this high-risk category; the complete protocol, including guidance by mutation status and consolidation pathways, is available in the full structured regimen below.
The primary objective is complete remission or complete remission with incomplete haematologic recovery (CR/CRi), defined as fewer than 5% blasts in the bone marrow. Response is assessed between day 14 and day 21 after the first induction cycle.